Evolus (EOLS)


Market Price (11/19/2026): $7.06 | Market Cap: $467.3 MilSector: Health Care | Industry: Pharmaceuticals

Evolus (EOLS)


Market Price (11/19/2026): $7.06
Market Cap: $467.3 Mil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Medical Aesthetics & Anti-Aging. Themes include Neurotoxin Treatments, Minimally Invasive Aesthetic Procedures, and Biopharmaceutical R&D.

Weak multi-year price returns
2Y Excs Rtn is -66%, 3Y Excs Rtn is -81%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.0%

Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2.7%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%

Key risks
EOLS key risks include [1] its precarious financial health and struggle to achieve profitability and [2] a critical dependence on a single-source supply chain for its key products.

0 Megatrend and thematic drivers
Megatrends include Medical Aesthetics & Anti-Aging. Themes include Neurotoxin Treatments, Minimally Invasive Aesthetic Procedures, and Biopharmaceutical R&D.
1 Weak multi-year price returns
2Y Excs Rtn is -66%, 3Y Excs Rtn is -81%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.0%
3 Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2.7%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%
5 Key risks
EOLS key risks include [1] its precarious financial health and struggle to achieve profitability and [2] a critical dependence on a single-source supply chain for its key products.

EOLS in ETFs

Weight = EOLS's share of each fund

VTI0.00%
ITOT0.00%
IWM0.01%
IWO0.03%
VTWO0.01%
SCHA0.01%
VHT0.01%
SCHB0.00%
+1 more covered ETF

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 18: up 5.7% in one day (S&P 500 down 0.3%)
This increase came without company news in our feed. The broader market moved down on this day.

Down 28.7% from its Sep 4 high to Nov 16, up 6.6% since (S&P 500 down 3.7%)
The stock saw a sustained decline, largely without company-specific news for most of the period. Key drops occurred on September 10 and October 2, with the trend culminating on November 5 following its Q3 earnings report.

Nov 5: down 9.0% the day after its Nov 4 earnings report (S&P 500 down 4.4%)
The stock fell after reporting a Q3 loss of $0.09 per share, missing estimates, though revenue beat expectations. This occurred on a day when the broader market was also significantly down, amid "growing concerns about AI."

Show more
Prices as of 11/18/2026

Nov 18: up 5.7% in one day (S&P 500 down 0.3%)
This increase came without company news in our feed. The broader market moved down on this day.

Down 28.7% from its Sep 4 high to Nov 16, up 6.6% since (S&P 500 down 3.7%)
The stock saw a sustained decline, largely without company-specific news for most of the period. Key drops occurred on September 10 and October 2, with the trend culminating on November 5 following its Q3 earnings report.

Nov 5: down 9.0% the day after its Nov 4 earnings report (S&P 500 down 4.4%)
The stock fell after reporting a Q3 loss of $0.09 per share, missing estimates, though revenue beat expectations. This occurred on a day when the broader market was also significantly down, amid "growing concerns about AI."

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 21.1% change in EOLS stock from 7/31/2026 to 11/18/2026 was primarily driven by a 13.8% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)5.847.0721.1%
Change Contribution By: 
Total Revenues ($ Mil)3023257.8%
P/S Multiple1.31.413.8%
Shares Outstanding (Mil)6566-1.4%
Cumulative Contribution21.1%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
EOLS21.1% 
Market (SPY)-2.0%36.5%
Sector (XLV)11.9%24.2%

Fundamental Drivers

The 31.2% change in EOLS stock from 4/30/2026 to 11/18/2026 was primarily driven by a 21.9% change in the company's P/S Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)5.397.0731.2%
Change Contribution By: 
Total Revenues ($ Mil)2973259.5%
P/S Multiple1.21.421.9%
Shares Outstanding (Mil)6566-1.8%
Cumulative Contribution31.2%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
EOLS31.2% 
Market (SPY)2.1%24.4%
Sector (XLV)25.1%25.2%

Fundamental Drivers

The 9.4% change in EOLS stock from 10/31/2025 to 11/18/2026 was primarily driven by a 17.1% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511182026Change
Stock Price ($)6.467.079.4%
Change Contribution By: 
Total Revenues ($ Mil)27832517.1%
P/S Multiple1.51.4-4.3%
Shares Outstanding (Mil)6566-2.3%
Cumulative Contribution9.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
EOLS9.4% 
Market (SPY)8.2%26.6%
Sector (XLV)27.7%20.7%

Fundamental Drivers

The -7.0% change in EOLS stock from 10/31/2023 to 11/18/2026 was primarily driven by a -44.0% change in the company's P/S Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)7.607.07-7.0%
Change Contribution By: 
Total Revenues ($ Mil)16932593.0%
P/S Multiple2.61.4-44.0%
Shares Outstanding (Mil)5766-13.9%
Cumulative Contribution-7.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
EOLS-7.0% 
Market (SPY)81.1%29.3%
Sector (XLV)52.9%29.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
EOLS Return94%15%40%5%-40%6%110%
Peers Return51%-39%-13%-10%2%-0%-26%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
EOLS Win Rate58%58%50%58%42%36% 
Peers Win Rate67%42%47%47%50%42% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
EOLS Max Drawdown-67%-53%-35%-38%-62%-41% 
Peers Max Drawdown-23%-57%-50%-48%-41%-43% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABBV, BHC, SKIN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventEOLSS&P 500
2023 SVB Regional Banking Crisis
  % Loss-20.7%-6.7%
  % Gain to Breakeven26.2%7.1%
  Time to Breakeven20 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-25.6%-24.5%
  % Gain to Breakeven34.5%32.4%
  Time to Breakeven10 days427 days
2020 COVID-19 Crash
  % Loss-65.7%-33.7%
  % Gain to Breakeven191.5%50.9%
  Time to Breakeven340 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-44.2%-19.2%
  % Gain to Breakeven79.1%23.8%
  Time to Breakeven45 days105 days

Compare to ABBV, BHC, SKIN

In The Past

Evolus's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventEOLSS&P 500
2023 SVB Regional Banking Crisis
  % Loss-20.7%-6.7%
  % Gain to Breakeven26.2%7.1%
  Time to Breakeven20 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-25.6%-24.5%
  % Gain to Breakeven34.5%32.4%
  Time to Breakeven10 days427 days
2020 COVID-19 Crash
  % Loss-65.7%-33.7%
  % Gain to Breakeven191.5%50.9%
  Time to Breakeven340 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-44.2%-19.2%
  % Gain to Breakeven79.1%23.8%
  Time to Breakeven45 days105 days

Compare to ABBV, BHC, SKIN

In The Past

Evolus's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Evolus (EOLS)

```html

Evolus, Inc. (EOLS) is a performance beauty company specializing in the medical aesthetics sector. The company focuses on developing and delivering innovative products that physicians use to provide aesthetic treatments to their patients.

The flagship product offered by Evolus is Jeuveau, a proprietary formulation of 900 kilodalton purified botulinum toxin type A. This product is specifically designed and approved for the temporary improvement in the appearance of moderate to severe glabellar lines, which are the frown lines between the eyebrows, in adult patients.

Evolus primarily serves the United States market, with its main customers being physicians and other medical professionals who then administer Jeuveau to their adult patients seeking cosmetic enhancements for facial lines.

```

AI Analysis | Feedback

  • The Pepsi to Botox's Coke in the wrinkle-relaxer market.
  • A focused challenger to AbbVie (the maker of Botox) in the aesthetic injectables space.

AI Analysis | Feedback

  • Jeuveau: A proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

AI Analysis | Feedback

Evolus (EOLS) sells primarily to other businesses rather than directly to individuals. Its major customers are medical professionals and aesthetic practices that administer Jeuveau to their patients.

The primary categories of customers include:

  • Dermatologists and Dermatology Practices: Physicians specializing in skin health and cosmetic procedures.
  • Plastic Surgeons and Plastic Surgery Centers: Medical professionals focused on reconstructive and cosmetic surgery.
  • Aesthetic Clinics and Medical Spas (Medspas): Facilities that offer a range of non-surgical cosmetic treatments, often overseen by medical directors.

These customers are typically private medical practices or clinics, and therefore do not have public company symbols.

AI Analysis | Feedback

Daewoong Pharmaceutical Co., Ltd. (069620)

AI Analysis | Feedback

David Moatazedi, President and Chief Executive Officer

Mr. Moatazedi has served as President and Chief Executive Officer of Evolus since May 2018. Prior to joining Evolus, he was Senior Vice President at Allergan, Inc., where he led the U.S. Medical Aesthetics division, overseeing a range of products from facial aesthetics to skin care. His tenure at Allergan also included roles such as Vice President of Sales and Marketing for both the U.S. Facial Aesthetics and Plastic Surgery divisions. Mr. Moatazedi's experience at Allergan included successful acquisitions such as LifeCell for $2.9 billion and ZELTIQ® Aesthetics for $2.5 billion. He also served as a board member at Obalon Therapeutics, Inc., a public medical device company. Earlier in his career, he spent six years at Novartis Pharmaceuticals.

Tatjana Mitchell, Chief Financial Officer

Ms. Mitchell was appointed Chief Financial Officer of Evolus, effective September 8, 2025. She brings over 20 years of strategic and operational finance leadership experience from both public and private companies in retail, consumer, data, and technology-driven sectors. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian, where she managed financial planning and capital allocation across six business units. During her time at Experian, she also held CFO roles for Experian Consumer Services and Experian Marketing Services, where she drove double-digit organic revenue growth and executed and integrated several acquisitions.

Michael Mazen Jafar, Chief Commercial Officer

Mr. Jafar was named Chief Commercial Officer effective November 1, 2020, and previously served as the company's Chief Marketing Officer since joining Evolus in June 2018. Before Evolus, Mr. Jafar was Vice President, Medical Aesthetics at Allergan, where he led the commercial launch of Juvederm Voluma® and managed product development and marketing initiatives for several key franchises, including Botox® Cosmetic and Kybella®. He also oversaw the market assessment and integration of the CoolSculpting® franchise acquired from Zeltiq.

Rui Avelar, Chief Medical Officer and Head of Research & Development

Dr. Avelar serves as the Chief Medical Officer and Head of Research & Development at Evolus. He participates in the company's earnings calls, providing insights into medical and R&D aspects.

Jeff Plumer, General Counsel

Mr. Plumer has served as General Counsel of Evolus since November 1, 2020. He previously held the role of Vice President of Legal since the company's initial public offering (IPO) in 2018. Prior to the IPO, he served as Vice President of Legal to Evolus' sole stockholder from 2014 to early 2018. Earlier in his career, Mr. Plumer practiced as a corporate securities and mergers & acquisitions attorney at K&L Gates LLP.

AI Analysis | Feedback

The key risks to Evolus's business include intense market competition, ongoing intellectual property and licensing dependencies, and challenges related to its financial health combined with an over-reliance on its primary product.

  1. Intense Market Competition and Aggressive Pricing Strategies: Evolus operates in a highly competitive medical aesthetics market, particularly for neurotoxins, which is dominated by established players like AbbVie's Botox. The entry of new competitors and their aggressive pricing strategies are expected to intensify pricing pressures, potentially leading to eroded profit margins and challenges in gaining or maintaining market share for Jeuveau.
  2. Intellectual Property Disputes and Reliance on Licensing Agreements: Evolus has a history of significant intellectual property disputes, including a U.S. International Trade Commission (ITC) ruling that previously imposed a 21-month ban on Jeuveau imports due to alleged trade secret misappropriation, though a settlement was later reached. Furthermore, the company's operations depend heavily on licensing agreements with partners like Daewoong and Symatese for product manufacturing and commercialization, which come with volume requirements and finite durations. Disruptions to these critical agreements or future IP challenges could severely impact Evolus's ability to operate and supply its products.
  3. Financial Health Challenges and Over-reliance on Jeuveau: Evolus has faced concerns regarding its financial health, including significant debt levels and reported negative profitability margins despite revenue growth. The company's business model is largely dependent on the success of a single product, Jeuveau. This concentrated reliance makes Evolus highly vulnerable to market shifts, increased competition, or any factors that could hinder Jeuveau's market adoption or profitability, thereby exacerbating existing financial challenges.

AI Analysis | Feedback

The launch and increasing market adoption of Revance Therapeutics' Daxxify (daxibotulinumtoxinA-lanm) represent a clear emerging threat to Evolus. Daxxify, approved in September 2022, is a botulinum toxin product for glabellar lines that offers a significantly longer duration of effect (median 6 months) compared to traditional neurotoxins like Evolus's Jeuveau (typically 3-4 months). This extended duration is a distinct competitive advantage that can attract both patients seeking fewer injection sessions and practitioners looking for improved patient satisfaction and clinic efficiency, thereby potentially eroding Jeuveau's market share.

AI Analysis | Feedback

Evolus, Inc. (EOLS) operates in the performance beauty sector, primarily offering medical aesthetic products. The company's main products are Jeuveau, a botulinum toxin type A formulation, and the Evolysse line of dermal fillers.

The addressable market sizes for Evolus's main products are as follows:

  • For Jeuveau, which is a botulinum toxin type A product for aesthetic use, the U.S. market for botulinum toxin was valued at approximately USD 5.04 billion in 2024 and is projected to reach around USD 11.53 billion by 2033. Globally, the botulinum toxin market was valued at approximately USD 12.24 billion in 2024 and is projected to reach about USD 30.59 billion by 2034.
  • For the Evolysse line of dermal fillers, the U.S. filler market was approximately USD 6.2 billion and is projected to grow to USD 10 billion by 2028.

AI Analysis | Feedback

Here are the expected drivers of future revenue growth for Evolus (EOLS) over the next 2-3 years:

  1. Continued U.S. Market Share Growth for Jeuveau: Evolus anticipates continued expansion of Jeuveau's market share in the U.S. The company has demonstrated consistent gains, with Jeuveau reaching over 14% of the U.S. market in 2025 and projected to move into the mid-teens. This growth is supported by the brand's performance beauty positioning, clinically differentiated product, and robust consumer loyalty programs like Evolus Rewards™, which shows high repeat engagement.
  2. Expansion of U.S. Injectable Portfolio with Evolysse and Estyme: The successful launch and increasing traction of Evolysse, a line of hyaluronic acid (HA) gels, is a significant driver. Evolysse is expected to contribute 10% to 12% of total revenue for 2026, with only two products (Form and Smooth) currently contributing to this. The planned FDA approval of Evolysse Sculpt, a mid-face volume product, later in 2026, and the upcoming introduction of Estyme, another HA gel in Europe in the first half of 2026, further diversify the company's portfolio and revenue streams. Evolus's portfolio rebate program also incentivizes clinics to adopt a broader range of its products.
  3. International Expansion: Evolus is actively growing its international presence, with international revenue nearly doubling in 2025 and accounting for 8% of total revenue, up from 5% in 2024. The company expects international revenue to reach approximately 15% by 2028. Operating in nine countries outside the United States, Evolus plans to continue expanding, including the European launch of Estyme in the first half of 2026.

AI Analysis | Feedback

Share Issuance

  • Evolus made equity awards to its directors and officers in February 2026, including 45,559 Restricted Stock Units (RSUs) to director Vikram Malik and 94,913 performance-based RSUs, 94,913 time-based RSUs, and stock options for 138,649 shares to officer Rui Avelar.
  • The company has a registration statement with the SEC covering shares of common stock available for future issuance under its 2017 Omnibus Incentive Plan.
  • Evolus management stated in March 2026 that the company is not planning to raise equity capital and remains highly sensitive to dilution.

Capital Expenditures

  • Capital spending for the purchase of property, plant, and equipment was $955,000 in the fourth quarter of 2025, representing a 118.0% increase year-over-year.
  • The company expects to allocate resources towards furthering the development of marketing programs and commercialization infrastructure for its products.
  • Evolus has committed to reimbursing Symatese for specific clinical trial expenses related to the Evolysse™ Lip and Eye products in the United States and certain regulatory filing fees in Europe.

Better Bets vs. Evolus (EOLS)

Peer Outperformance in Pharmaceuticals

EOLS has outperformed 64% of its 59 Pharmaceuticals peers over 5Y. Among the peers that beat it is PTCT. Pharmaceuticals ranks 7th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Pharmaceuticals constituents that EOLS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
61%
of 69 industry peers · 0.6% return
3Y
39%
of 64 industry peers · -24.6% return
5Y
64%
of 59 industry peers · 7.1% return
Pharmaceuticals peers with revenue growth within 4pp of EOLS's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
EOLS Evolus 21.1% -15.0x 0.6%-24.6%7.1% —
PTCT PTC Therapeutics 25.1% -47.4x -21.5%194.4%52.8% +46pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Pharmaceuticals is EOLS's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals ← 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

EOLSABBVBHCSKINMedian
NameEvolus AbbVie Bausch H.SkinHeal. 
Mkt Price7.06285.808.7312.4810.61
Mkt Cap0.5505.63.30.11.9
Rev LTM32566,01411,1132895,719
Op Inc LTM-1623,7493,01971,513
FCF LTM-918,8721,82718923
FCF 3Y Avg-3118,0601,30713660
CFO LTM-320,0892,209241,116
CFO 3Y Avg-2519,1531,70019860

Growth & Margins

EOLSABBVBHCSKINMedian
NameEvolus AbbVie Bausch H.SkinHeal. 
Rev Chg LTM13.9%10.7%10.8%-4.4%10.7%
Rev Chg 3Y Avg21.1%6.3%9.2%-10.2%7.7%
Rev Chg Q13.0%10.3%9.7%-2.1%10.0%
QoQ Delta Rev Chg LTM2.8%2.5%2.4%-0.5%2.5%
Op Inc Chg LTM57.4%65.3%45.6%124.6%61.3%
Op Inc Chg 3Y Avg19.2%17.8%26.5%73.4%22.8%
Op Mgn LTM-5.0%36.0%27.2%2.4%14.8%
Op Mgn 3Y Avg-10.3%29.2%22.1%-9.9%6.1%
QoQ Delta Op Mgn LTM1.5%2.0%2.0%3.9%2.0%
CFO/Rev LTM-0.8%30.4%19.9%8.2%14.0%
CFO/Rev 3Y Avg-9.1%31.7%16.5%6.5%11.5%
FCF/Rev LTM-2.7%28.6%16.4%6.3%11.4%
FCF/Rev 3Y Avg-11.1%29.9%12.6%4.6%8.6%

Valuation

EOLSABBVBHCSKINMedian
NameEvolus AbbVie Bausch H.SkinHeal. 
Mkt Cap0.5505.63.30.11.9
P/S1.47.70.30.30.9
P/Op Inc-28.821.31.111.86.4
P/EBIT-33.432.02.66.74.7
P/E-15.048.9-3.9-4.4-4.2
P/CFO-176.425.21.53.42.5
Total Yield-6.7%4.4%-25.7%-22.5%-14.6%
Dividend Yield0.0%2.4%0.0%0.0%0.0%
FCF Yield 3Y Avg-6.3%4.5%54.1%9.4%6.9%
D/E0.40.26.33.31.8
Net D/E0.30.15.61.91.1

Returns

EOLSABBVBHCSKINMedian
NameEvolus AbbVie Bausch H.SkinHeal. 
1M Rtn-4.1%1.1%38.1%18.3%9.7%
3M Rtn-17.9%8.1%26.7%4.9%6.5%
6M Rtn7.1%36.4%58.7%-7.9%21.8%
12M Rtn0.4%25.9%41.3%-52.4%13.1%
3Y Rtn-24.7%128.3%26.5%-72.4%0.9%
1M Excs Rtn-0.4%2.7%39.8%15.7%9.2%
3M Excs Rtn-12.5%12.8%31.1%2.0%7.4%
6M Excs Rtn7.4%36.6%58.9%-7.7%22.0%
12M Excs Rtn-9.6%14.6%31.3%-62.0%2.5%
3Y Excs Rtn-81.1%59.7%-34.4%-152.2%-57.8%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Jeuveau ®272264200  
Evolysse ®2300  
Service revenue22221
Product revenue, net   14799
Total297266202149100


Assets by Segment
$ Mil201820172016
Single segment17215277
Total17215277


Price Behavior

Price Behavior
Market Price$7.07 
Market Cap ($ Bil)0.5 
First Trading Date02/08/2018 
Distance from 52W High-24.0% 
   50 Days200 Days
DMA Price$7.49$6.40
DMA Trenddownup
Distance from DMA-5.6%10.5%
 3M1YR
Volatility53.9%67.5%
Downside Capture231.93120.84
Upside Capture147.93100.64
Correlation (S&P 500)53.2%27.8%
EOLS Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.851.581.170.581.141.12
Up Beta-2.82-0.530.490.181.331.08
Down Beta1.932.494.251.361.621.31
Up Capture145%91%115%77%83%73%
Bmk +ve Days12182862130427
Stock +ve Days12213564125369
Down Capture236%224%-18%1%93%104%
Bmk -ve Days10253664121325
Stock -ve Days10222860124373

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with EOLS
EOLS1.7%67.5%0.28-
Sector ETF (XLV)21.5%17.0%0.9620.4%
Equity (SPY)10.9%13.8%0.4927.0%
Gold (GLD)-8.2%29.0%-0.304.4%
Commodities (DBC)28.8%21.5%1.07-16.0%
Real Estate (VNQ)11.2%14.2%0.5010.3%
Bitcoin (BTCUSD)-29.6%43.7%-0.6921.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with EOLS
EOLS-0.9%62.2%0.23-
Sector ETF (XLV)8.0%15.4%0.3327.8%
Equity (SPY)11.0%17.3%0.4630.4%
Gold (GLD)14.5%19.2%0.605.2%
Commodities (DBC)6.8%19.6%0.240.4%
Real Estate (VNQ)1.1%19.0%-0.0526.0%
Bitcoin (BTCUSD)-0.0%51.4%0.1817.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with EOLS
EOLS-4.7%79.7%0.28-
Sector ETF (XLV)12.1%16.8%0.5924.9%
Equity (SPY)14.9%18.0%0.7028.0%
Gold (GLD)10.9%16.6%0.534.2%
Commodities (DBC)7.2%18.2%0.315.7%
Real Estate (VNQ)5.8%20.7%0.2425.6%
Bitcoin (BTCUSD)57.1%66.3%0.9712.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity6.0 Mil
Short Interest: % Change Since 10152026-6.0%
Average Daily Volume0.6 Mil
Days-to-Cover Short Interest9.4 days
Basic Shares Quantity66.1 Mil
Short % of Basic Shares9.1%

Returns Analyses

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-9.0%-0.7% 
8/5/202619.9%31.4%46.4%
5/4/202614.2%13.3%8.1%
3/3/202635.4%27.8%4.4%
1/9/2026-1.6%-12.9%-26.1%
11/5/20255.4%7.2%2.3%
8/5/2025-28.5%-28.2%-15.7%
5/7/2025-14.2%-15.1%-14.6%
...
SUMMARY STATS   
# Positive121111
# Negative141514
Median Positive13.6%13.3%18.7%
Median Negative-8.2%-10.7%-14.7%
Max Positive35.4%34.6%46.4%
Max Negative-28.5%-28.2%-44.5%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-9.0%-0.7% 
8/5/202619.9%31.4%46.4%
5/4/202614.2%13.3%8.1%
3/3/202635.4%27.8%4.4%
1/9/2026-1.6%-12.9%-26.1%
11/5/20255.4%7.2%2.3%
8/5/2025-28.5%-28.2%-15.7%
5/7/2025-14.2%-15.1%-14.6%
3/4/2025-1.3%-11.4%-14.8%
11/6/2024-15.0%-27.1%-24.7%
7/31/202413.0%3.9%27.5%
5/7/2024-1.2%-4.8%-7.6%
3/7/2024-4.9%-4.9%-10.1%
1/16/202419.7%12.7%29.6%
11/7/20238.2%4.6%18.7%
8/2/20232.1%-5.8%0.5%
5/9/202316.0%7.1%-5.4%
3/8/2023-3.2%-3.4%-5.3%
1/18/202318.1%27.5%10.8%
11/8/2022-9.1%-3.1%-2.3%
8/2/2022-17.6%-26.1%-21.8%
5/10/20227.7%34.6%18.7%
3/3/20225.7%16.4%29.7%
11/2/2021-4.5%-10.7%-34.5%
8/4/2021-7.5%-4.1%-7.9%
3/24/2021-23.1%-21.3%-44.5%
SUMMARY STATS   
# Positive121111
# Negative141514
Median Positive13.6%13.3%18.7%
Median Negative-8.2%-10.7%-14.7%
Max Positive35.4%34.6%46.4%
Max Negative-28.5%-28.2%-44.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/04/202610-Q
12/31/202503/03/202610-K
09/30/202511/05/202510-Q
06/30/202508/05/202510-Q
03/31/202505/07/202510-Q
12/31/202403/04/202510-K
09/30/202411/06/202410-Q
06/30/202407/31/202410-Q
03/31/202405/07/202410-Q
12/31/202303/07/202410-K
09/30/202311/07/202310-Q
06/30/202308/02/202310-Q
03/31/202305/09/202310-Q
12/31/202203/08/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/04/202610-Q
12/31/202503/03/202610-K
09/30/202511/05/202510-Q
06/30/202508/05/202510-Q
03/31/202505/07/202510-Q
12/31/202403/04/202510-K
09/30/202411/06/202410-Q
06/30/202407/31/202410-Q
03/31/202405/07/202410-Q
12/31/202303/07/202410-K
09/30/202311/07/202310-Q
06/30/202308/02/202310-Q
03/31/202305/09/202310-Q
12/31/202203/08/202310-K
09/30/202211/08/202210-Q
06/30/202208/02/202210-Q
03/31/202205/10/202210-Q
12/31/202103/03/202210-K
09/30/202111/02/202110-Q
06/30/202108/04/202110-Q
03/31/202105/12/202110-Q
12/31/202003/25/202110-K
09/30/202010/29/202010-Q
06/30/202008/10/202010-Q
03/31/202005/11/202010-Q
12/31/201902/25/202010-K

Recent Forward Guidance

Updated 11/5/2026

Latest: Q3 2026 Earnings Reported 11/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Total Net RevenueReported330.00 Mil333.50 Mil337.00 Mil0.0% AffirmedGuidance: 333.50 Mil for 2026
2026 Revenue GrowthReported11.0%12.0%13.0%   
2026 HA Gels Total Net Revenue Contribution PercentageReported0.10.110.12   
2026 Adjusted Gross Profit MarginReported67.0%67.25%67.5% 0.0%AffirmedGuidance: 67.25% for 2026
2026 Non-GAAP Operating ExpensesReported210.00 Mil211.50 Mil213.00 Mil-1.2% LoweredGuidance: 214.00 Mil for 2026
2026 Non-GAAP Operating Expenses GrowthReported0.0%1.0%2.0%   
2026 Adjusted EBITDA MarginReported      
2028 Total Net RevenueReported450.00 Mil475.00 Mil500.00 Mil0.0% AffirmedGuidance: 475.00 Mil for 2028
2028 Three-Year Net Revenue CAGRReported0.150.170.19   
2028 Adjusted EBITDA MarginReported13.0%14.0%15.0% 0.0%AffirmedGuidance: 14.0% for 2028


Prior: Q1 2026 Earnings Reported 5/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported327.00 Mil332.00 Mil337.00 Mil0 AffirmedGuidance: 332.00 Mil for 2026
2026 Revenue GrowthReported10.0%11.5%13.0% 0AffirmedGuidance: 11.5% for 2026
2026 Adjusted Gross Profit MarginReported65.5%66.25%67.0%   
2026 Non-GAAP Operating ExpensesReported210.00 Mil213.00 Mil216.00 Mil0 AffirmedGuidance: 213.00 Mil for 2026
2028 RevenueReported450.00 Mil475.00 Mil500.00 Mil0 AffirmedGuidance: 475.00 Mil for 2028
2028 Revenue GrowthReported15.0%17.0%19.0%   
2028 Adjusted EBITDA MarginReported13.0%14.0%15.0% 0AffirmedGuidance: 14.0% for 2028

Q4 2025 Earnings Reported 3/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported327.00 Mil332.00 Mil337.00 Mil0 AffirmedGuidance: 332.00 Mil for 2026
2026 Revenue GrowthReported10.0%11.5%13.0% -0.5%LoweredGuidance: 12.0% for 2026
2026 Non-GAAP Operating ExpensesReported210.00 Mil213.00 Mil216.00 Mil   
2026 Adjusted EBITDA MarginReported1.0%3.0%5.0%   
2028 RevenueReported450.00 Mil475.00 Mil500.00 Mil0 AffirmedGuidance: 475.00 Mil for 2028
2028 Adjusted EBITDA MarginReported13.0%14.0%15.0%   

Insider Activity

Updated 9/4/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Moatazedi, DavidSee RemarksDirectSell90420269.04105,108950,0194,515,562Form
2Avelar, RuiSee RemarksDirectSell32020264.753,11914,8152,030,259Form
3Moatazedi, DavidSee RemarksDirectSell32020264.7513,66964,9292,872,385Form
4Moatazedi, DavidSee RemarksDirectSell31820264.89116,720570,5623,022,773Form
5Avelar, RuiSee RemarksDirectSell31820264.8929,996146,6292,104,618Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Moatazedi, DavidSee RemarksDirectSell90420269.04105,108950,0194,515,562Form
2Avelar, RuiSee RemarksDirectSell32020264.753,11914,8152,030,259Form
3Moatazedi, DavidSee RemarksDirectSell32020264.7513,66964,9292,872,385Form
4Moatazedi, DavidSee RemarksDirectSell31820264.89116,720570,5623,022,773Form
5Avelar, RuiSee RemarksDirectSell31820264.8929,996146,6292,104,618Form
6Moatazedi, DavidSee RemarksDirectSell122920257.1510,53975,3612,534,122Form
7Avelar, RuiSee RemarksDirectSell122920257.152,26116,1682,551,520Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Frazier Life Sciences Management, L.P.$10.8 Mil0.3%38Hold13F
Active Manager
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Frazier Life Sciences Management, L.P.$10.8 Mil0.3%38Hold13F
Core Cache Last Updated: 11/18/2026